Ergocalciferol
Small molecule targets VDR via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DRISDOL | — | 1941-01-11 | fda.gov ↗ |
Trials 47 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04450199 Comparator | Jul 2020 → Dec 2023 | vitamin D deficiency | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01578473 Comparator | May → Jul 2013 | Peyronie disease | Men's Health Boston | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05619289 Comparator | Apr 2023 → Jan 2026 | chronic pain syndrome | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT05458024 Comparator | Jan 2023 → May 2024 | musculoskeletal system disorder | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02074631 Background | Feb 2015 → Oct 2022 | osteoporosis | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01173848 Comparator | Jul 2010 → Sep 2011 | chronic kidney disease | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05313477 Comparator | May 2022 → Aug 2023 | chronic hepatitis B virus infection, vitamin D deficiency | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT03073369 Comparator | Jan → Dec 2018 | anemia, chronic kidney disease, iron metabolism disease | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 4 | NCT01114672 Comparator | Jul 2010 → Nov 2011 | — | Winthrop University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00958451 Comparator | Jul 2009 → Jan 2011 | chronic kidney disease, secondary hyperparathyroidism of renal origin | Salem Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00882401 Comparator | Apr 2009 → Oct 2010 | chronic kidney disease, vitamin D deficiency | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT01799317 Comparator | Mar 2009 → Jun 2014 | abnormal mineralization disorder | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 4 | NCT00424619 Comparator | Oct 2007 → Jul 2009 | — | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT01153243 Comparator | Apr 2007 → Jun 2010 | diabetes mellitus, vitamin D deficiency | Cook County Health | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT02827643 Comparator | Jun 2016 → Mar 2017 | bone disorder | Mahidol University | Unknown | No outcome recorded |
| — | NCT02414529 Comparator | Nov 2013 → Oct 2015 | vitamin D deficiency | NYU Langone Health | Completed | No outcome recorded |
| — | NCT01170494 Comparator | Feb 2013 → Apr 2016 | vitamin D deficiency | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT01337635 Comparator | Nov 2010 → Dec 2012 | atopic eczema, vitamin D deficiency | Medical College of Wisconsin | Terminated | No outcome recorded |
| — | NCT01426347 Comparator | Jan 2009 → Jan 2012 | rheumatoid arthritis, vitamin D deficiency | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT01570309 Comparator | Aug 2008 → Mar 2011 | coronary artery disorder, vitamin D deficiency | Seth I. Sokol, M.D. | Completed | No outcome recorded |
| — | NCT00450073 Comparator | Nov 2006 → May 2011 | cystic fibrosis | Atlanta VA Medical Center | Completed | No outcome recorded |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 72 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ergocalciferol | “Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer” NCT00944424 ↗45“Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months” NCT01474486 ↗ “Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem” NCT00715429 ↗ “Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months” NCT01029002 ↗ “The most commonly prescribed medication to replete vitamin D deficiency is oral ergocalciferol.” NCT02435771 ↗ “300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.” NCT05458024 ↗ “ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks” NCT01107808 ↗ “Ergocalciferol 300,000 IU single oral dose” NCT01337635 ↗ |
| Known as | calciferol | “vitamin D2 ( calciferol )” NCT05260255 ↗ |
| Known as | Deltalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | DRISDOL | “The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or...” NCT03066817 ↗1“Drisdol (Ergocalciferol) Vitamin D2” NCT01217840 ↗ |
| Known as | Eciferol d2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Ergo-d2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Ergocalciferol component of vitaped | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Ergocalciferols | “Drug: Ergocalciferols” NCT01268111 ↗ |
| Known as | Ergocalciferolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Ergoral d2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Ergorone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | NSC-62792 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Ostelin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Sterogyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Sterogyl 15h | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Sterogyl-15 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Uvesterol d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Viosterol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Vit D2 | “Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood...” NCT01633853 ↗ |
| Known as | Vitamin D | “Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months” NCT01474486 ↗2“The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.” NCT00157066 ↗ “Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months” NCT01029002 ↗ |
| Known as | Vitamin d (ergocalciferol) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Vitamin d nos | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | Vitamin d, unspecified form | ChEMBL registry synonym — accepted as the source's own label CHEMBL1536 ↗ |
| Known as | vitamin D2 | “Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer” NCT00944424 ↗31“Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks” NCT02827643 ↗ “Because of this, we studied whether vitamin D2 treatment with ergocalciferol is effective for relief of uremic pruritus severity as measured by pruritus severity surveys.” PMID 23453391 ↗ Feb 2013 “Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem” NCT00715429 ↗ “Vitamin D2 (Ergocalciferol) is approved by the FDA to treat Vitamin D deficiency and will be given according to approved labeling.” NCT01568255 ↗ “investigating the impact of high-dose vitamin D2 (ergocalciferol) supplementation as an adjunctive therapy” NCT07369063 ↗ “The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency” NCT01263028 ↗ “50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.” NCT01295034 ↗ “50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months” NCT04472481 ↗ “Group 1: Vitamin D2 50000 units per tablet” NCT06618365 ↗ “Vitamin D2 20000IU 1 tab oral weekly” NCT04591847 ↗ “Drisdol (Ergocalciferol) Vitamin D2” NCT01217840 ↗ “ergocalciferol (vitamin D2)” NCT07366450 ↗ “Drug: Vitamin D 2” NCT04591847 ↗ |
| Known as | Vitamin D2 =ergocalciferol | “Vitamin D2 =ergocalciferol” NCT01107808 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL1536 ↗ |
| Modality | Small molecule | “Vitamin D is one of the main groups of sterols” PMID 29280010 ↗ Dec 2017 |
| Route | Oral | “Participants were randomized to receive a single oral dose of 2.5 mg vitamin D or placebo and followed up at 6 weeks.” PMID 17463418 ↗ Apr 2007 |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL1536 ↗ |